Sign in or create an account to add this stock to your watchlist.
About Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. It is also developing ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ITCI
CUSIPN/A
Phone646-440-9333
Debt
Debt-to-Equity RatioN/A
Current Ratio22.55
Quick Ratio22.55
Price-To-Earnings
Trailing P/E Ratio-10.37
Forward P/E Ratio-6.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$250,000.00
Price / Sales4,745.77
Cash FlowN/A
Price / CashN/A
Book Value$8.33 per share
Price / Book2.60
Profitability
EPS (Most Recent Fiscal Year)($2.12)
Net Income$-97,770,000.00
Net Margins-39,745.53%
Return on Equity-27.67%
Return on Assets-26.57%
Miscellaneous
Employees49
Outstanding Shares54,700,000
Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions
What is Intra-Cellular Therapies' stock symbol?
Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."
How were Intra-Cellular Therapies' earnings last quarter?
Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.01. Intra-Cellular Therapies had a negative return on equity of 27.67% and a negative net margin of 39,745.53%. View Intra-Cellular Therapies' Earnings History.
When is Intra-Cellular Therapies' next earnings date?
What price target have analysts set for ITCI?
10 Wall Street analysts have issued twelve-month price targets for Intra-Cellular Therapies' shares. Their predictions range from $24.00 to $36.00. On average, they expect Intra-Cellular Therapies' stock price to reach $29.10 in the next twelve months. View Analyst Ratings for Intra-Cellular Therapies.
What are Wall Street analysts saying about Intra-Cellular Therapies stock?
Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:
- 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (5/8/2018)
- 2. Cantor Fitzgerald analysts commented, "Lumateperone NDA filing still expected in mid-2018. We view the pre- NDA meeting (and what may be said thereafter), the actual filing and the FDA acceptance of it (presumably) as minor events that are expected and not stock moving." (3/1/2018)
- 3. SunTrust Banks analysts commented, "Meeting with FDA could help identify the path forward for ralinepag. On the 3Q17 results conference call, management commented that the company will seek a meeting with the FDA to determine the pivotal development plan for ralinepag. Specific timing of the meeting is pending FDA scheduling but management laid out their views on the drug candidate’s development program. Key considerations include 1) accelerating time to market, 2) maximizing the breadth and scope of label, 3) raising physician awareness of the compound and 4) comparing ralinepag with other available treatments." (11/8/2017)
Who are some of Intra-Cellular Therapies' key competitors?
Some companies that are related to Intra-Cellular Therapies include Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD) and Portola Pharmaceuticals (PTLA).
Who are Intra-Cellular Therapies' key executives?
Intra-Cellular Therapies' management team includes the folowing people:
- Dr. Sharon Mates Ph.D., Co-Founder, Chairman, CEO & Pres (Age 65)
- Mr. Lawrence J. Hineline CPA, VP of Fin., CFO, Treasurer & Assistant Sec. (Age 62)
- Dr. Robert E. Davis Ph.D., Sr. VP & Chief Scientific Officer (Age 67)
- Mr. Michael I. Halstead J.D., Sr. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 45)
- Dr. Kimberly E. Vanover Ph.D., Sr. VP of Clinical Devel. (Age 52)
Has Intra-Cellular Therapies been receiving favorable news coverage?
Media stories about ITCI stock have been trending somewhat positive this week, according to Accern. The research group ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intra-Cellular Therapies earned a news sentiment score of 0.19 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Intra-Cellular Therapies' major shareholders?
Intra-Cellular Therapies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.86%), Wasatch Advisors Inc. (3.44%), PointState Capital LP (3.42%), Dimensional Fund Advisors LP (2.19%), Columbus Circle Investors (1.02%) and Northern Trust Corp (0.90%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.
Which major investors are selling Intra-Cellular Therapies stock?
ITCI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., JPMorgan Chase & Co., Dimensional Fund Advisors LP, C WorldWide Group Holding A S, DekaBank Deutsche Girozentrale, GSA Capital Partners LLP and Federated Investors Inc. PA. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.
Which major investors are buying Intra-Cellular Therapies stock?
ITCI stock was acquired by a variety of institutional investors in the last quarter, including PointState Capital LP, Columbus Circle Investors, Hsbc Holdings PLC, Engineers Gate Manager LP, ETF Managers Group LLC, D.A. Davidson & CO., Atlantic Trust Group LLC and New York State Common Retirement Fund. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies.
How do I buy shares of Intra-Cellular Therapies?
Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intra-Cellular Therapies' stock price today?
One share of ITCI stock can currently be purchased for approximately $21.70.
How big of a company is Intra-Cellular Therapies?
Intra-Cellular Therapies has a market capitalization of $1.23 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-97,770,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Intra-Cellular Therapies employs 49 workers across the globe.
How can I contact Intra-Cellular Therapies?
Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]
MarketBeat Community Rating for Intra-Cellular Therapies (ITCI)
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Intra-Cellular Therapies (NASDAQ:ITCI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Intra-Cellular Therapies in the last 12 months. Their average twelve-month price target is $29.10, suggesting that the stock has a possible upside of 34.16%. The high price target for ITCI is $36.00 and the low price target for ITCI is $24.00. There are currently 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.91 | 2.90 | 2.88 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $29.10 | $29.10 | $27.4444 | $26.1429 |
| Price Target Upside: | 34.16% upside | 51.40% upside | 67.45% upside | 78.33% upside |
Intra-Cellular Therapies (NASDAQ:ITCI) Consensus Price Target History
Intra-Cellular Therapies (NASDAQ:ITCI) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Intra-Cellular Therapies (NASDAQ:ITCI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Intra-Cellular Therapies (NASDAQ ITCI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 71.57%
Intra-Cellular Therapies (NASDAQ ITCI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/16/2018 | Lawrence J Hineline | VP | Sell | 49,700 | $20.02 | $994,994.00 | |  |
| 1/22/2018 | Michael Halstead | SVP | Sell | 25,500 | $18.03 | $459,765.00 | 191 | |
| 1/8/2018 | Kimberly E Vanover | SVP | Sell | 772 | $17.46 | $13,479.12 | 12,373 | |
| 1/8/2018 | Sharon Mates | Chairman | Sell | 6,604 | $17.48 | $115,437.92 | 1,088,707 | |
| 1/5/2018 | Kimberly E Vanover | SVP | Sell | 1,185 | $17.37 | $20,583.45 | 26,803 | |
| 1/5/2018 | Sharon Mates | Chairman | Sell | 11,257 | $17.08 | $192,269.56 | 1,099,964 | |
| 1/4/2018 | Lawrence J Hineline | CFO | Sell | 3,192 | $15.67 | $50,018.64 | 68,686 | |
| 12/29/2017 | Christopher D Alafi | Director | Buy | 1,001 | $14.48 | $14,494.48 | | |
| 12/11/2017 | Richard A Lerner | Director | Sell | 7,000 | $15.09 | $105,630.00 | 8,621 | |
| 12/5/2017 | Robert E Davis | SVP | Sell | 650 | $15.00 | $9,750.00 | 28,514 | |
| 11/22/2017 | Christopher D Alafi | Director | Buy | 10,000 | $15.55 | $155,500.00 | 744,466 | |
| 10/30/2017 | Sharon Mates | CEO | Sell | 18,750 | $15.75 | $295,312.50 | 1,107,457 | |
| 10/2/2017 | Alafi Capital Co Llc | Major Shareholder | Buy | 258,065 | $15.50 | $4,000,007.50 | 3,953,270 | |
| 1/5/2017 | Lawrence J Hineline | VP | Sell | 1,918 | $16.58 | $31,800.44 | 63,389 | |
| 1/5/2017 | Michael Halstead | SVP | Sell | 1,601 | $16.55 | $26,496.55 | 21,506 | |
| 1/5/2017 | Sharon Mates | Chairman | Sell | 4,081 | $16.55 | $67,540.55 | 1,088,707 | |
| 12/15/2016 | Kimberly E Vanover | SVP | Sell | 9,375 | $15.23 | $142,781.25 | 5,000 | |
| 12/7/2016 | Alafi Capital Co Llc | Major Shareholder | Buy | 65,000 | $16.27 | $1,057,550.00 | 3,674,379 | |
| 11/14/2016 | Christopher D Alafi | Director | Buy | 34,000 | $14.50 | $493,000.00 | 730,529 | |
| 2/29/2016 | Christopher D Alafi | Director | Buy | 100,000 | $29.70 | $2,970,000.00 | 728,828 | |
| 12/15/2015 | Lawrence J. Hineline | CFO | Sell | 45,000 | $51.45 | $2,315,250.00 | 62,200 | |
| 12/11/2015 | Sharon Mates | CEO | Sell | 51,500 | $53.87 | $2,774,305.00 | 1,086,185 | |
| 12/8/2015 | Joel S Marcus | Director | Sell | 92,700 | $54.47 | $5,049,369.00 | 18,722 | |
| 11/24/2015 | Lawrence J Hineline | CFO | Sell | 5,000 | $55.00 | $275,000.00 | 59,700 | |
| 6/8/2015 | Lawrence P Wennogle | VP | Sell | 25,000 | $26.84 | $671,000.00 | | |
| 3/11/2015 | Christopher D Alafi | Director | Buy | 625,000 | $24.00 | $15,000,000.00 | | |
| 12/9/2014 | Lawrence J Hineline | CFO | Sell | 22,500 | $16.71 | $375,975.00 | | |
| 12/1/2014 | Moshe Alafi | Major Shareholder | Buy | 1,422 | $14.75 | $20,974.50 | | |
| 11/28/2014 | Christopher D Alafi | Director | Buy | 35,000 | $14.75 | $516,250.00 | | |
| 11/19/2014 | Alafi Capital Co Llc | Major Shareholder | Buy | 1,034 | $14.25 | $14,734.50 | | |
| 11/18/2014 | Alafi Capital Co Llc | Major Shareholder | Buy | 3,664 | $14.26 | $52,248.64 | | |
| 11/13/2014 | Alafi Capital Co Llc | Major Shareholder | Buy | 12,200 | $15.34 | $187,148.00 | | |
| 11/6/2014 | Michael Halstead | SVP | Buy | 20,000 | $15.38 | $307,600.00 | | |
| 10/15/2014 | Lawrence P Wennogle | VP | Sell | 3,604 | $15.00 | $54,060.00 | | |
| 10/13/2014 | Lawrence P Wennogle | VP | Sell | 1,600 | $15.00 | $24,000.00 | | |
| 10/8/2014 | Lawrence P Wennogle | VP | Sell | 4,745 | $15.00 | $71,175.00 | | |
| 10/6/2014 | Lawrence P Wennogle | VP | Sell | 16,499 | $15.00 | $247,485.00 | | |
| 9/15/2014 | Lawrence P Wennogle | VP | Sell | 5,000 | $15.00 | $75,000.00 | | |
| 9/8/2014 | Lawrence J Hineline | CFO | Sell | 300 | $15.00 | $4,500.00 | | |
| 5/22/2014 | Lawrence P Wennogle | VP | Sell | 6,000 | $15.00 | $90,000.00 | | |
(Data available from 1/1/2013 forward)
Intra-Cellular Therapies (NASDAQ ITCI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Intra-Cellular Therapies (ITCI) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - May 17 at 4:51 PM |
| Intra-Cellular Therapies (ITCI) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 16 at 11:04 AM |
| -$0.77 Earnings Per Share Expected for Intra-Cellular Therapies Inc (ITCI) This Quarter
www.americanbankingnews.com - May 16 at 3:12 AM |
| ValuEngine Lowers Intra-Cellular Therapies (ITCI) to Hold
www.americanbankingnews.com - May 11 at 9:23 PM |
 | Intra-Cellular Therapies to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 9 at 8:35 AM |
| Intra-Cellular Therapies (ITCI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 8 at 7:04 AM |
| Intra-Cellular Therapies Inc (ITCI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 6 at 8:00 PM |
| Intra-Cellular Therapies (ITCI) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 4 at 8:15 PM |
| Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical Conferences
finance.yahoo.com - May 4 at 8:32 AM |
| Intra-Cellular Therapies (ITCI) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - May 4 at 12:17 AM |
| Intra-Cellular: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 5:11 PM |
| Intra-Cellular Therapies Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 3 at 8:30 AM |
| Intra-Cellular Therapies (ITCI) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 28 at 7:40 AM |
 | Benzinga's Daily Biotech Pulse: Intra-cellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences
www.msn.com - April 27 at 8:49 AM |
| ValuEngine Lowers Intra-Cellular Therapies (ITCI) to Sell
www.americanbankingnews.com - April 26 at 2:04 PM |
| Intra-Cellular Therapies Presents Data on ITI-214 at the 2018 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 26 at 8:29 AM |
| Traders Buy Large Volume of Call Options on Intra-Cellular Therapies (ITCI)
www.americanbankingnews.com - April 19 at 8:32 AM |
| Intra-Cellular Therapies Sees Unusually Large Options Volume (ITCI)
www.americanbankingnews.com - April 19 at 8:32 AM |
 | Notable Tuesday Option Activity: ALGN, TWTR, ITCI
www.nasdaq.com - April 17 at 5:42 PM |
| Intra-Cellular Therapies (ITCI) Given a $10.00 Price Target at Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM |
| Intra-Cellular Therapies (ITCI) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:11 PM |
| Intra-Cellular Therapies (ITCI) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 7 at 11:22 AM |
| Intra-Cellular Therapies Inc (ITCI) to Post FY2020 Earnings of ($2.01) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 5 at 9:17 AM |
 | Pre-Market Technical Scan on Biotech Equities -- INSYS Therapeutics, Intellia Therapeutics, Intercept Pharma, and ...
www.prnewswire.com - April 4 at 4:01 PM |
| Intra-Cellular Therapies (ITCI) Given a $25.00 Price Target at Leerink Swann
www.americanbankingnews.com - April 4 at 8:04 AM |
| Canaccord Genuity Analysts Give Intra-Cellular Therapies (ITCI) a $31.00 Price Target
www.americanbankingnews.com - April 3 at 10:36 AM |
| Here's Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing Today
finance.yahoo.com - April 2 at 5:14 PM |
 | Pre-Market Technical Scan on Biotech Equities -- INSYS Therapeutics, Intellia Therapeutics, Intercept Pharma, and Intra-Cellular Therapies
www.bizjournals.com - April 2 at 9:00 AM |
 | Intra-Cellular down 7% premarket on FDA rejection of Alkermes' application for MDD med ALKS 5461
seekingalpha.com - April 2 at 9:00 AM |
| Intra-Cellular Therapies (ITCI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 1 at 1:36 PM |
| SunTrust Banks Upgrades Intra-Cellular Therapies (ITCI) to Buy
www.americanbankingnews.com - April 1 at 9:46 AM |
| BidaskClub Downgrades Intra-Cellular Therapies (ITCI) to Hold
www.americanbankingnews.com - March 30 at 11:07 AM |
| Intra-Cellular Therapies (ITCI) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 26 at 10:58 PM |
| Intra-Cellular Therapies (ITCI) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 1:37 PM |
| Intra-Cellular Therapies Inc (ITCI) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 17 at 7:38 PM |
| Intra-Cellular Therapies (ITCI) Lifted to Buy at BidaskClub
www.americanbankingnews.com - March 17 at 5:36 PM |
| Wired News – FDA Approved Intra-Cellular’s Rolling NDA Submission for Lumateperone for Schizophrenia
finance.yahoo.com - March 15 at 8:33 AM |
 | Intra-Cellular Therapies (ITCI) Announces Positive Pre-NDA Meeting with FDA for Lumateperone
www.streetinsider.com - March 13 at 7:05 PM |
| Canaccord Genuity Reiterates $31.00 Price Target for Intra-Cellular Therapies (ITCI)
www.americanbankingnews.com - March 13 at 3:46 PM |
| Intra-Cellular Therapies (ITCI) Announces Positive Pre-NDA Meeting with FDA for Lumateperone - StreetInsider.com
www.streetinsider.com - March 13 at 8:43 AM |
| Intra-Cellular Therapies Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia
finance.yahoo.com - March 13 at 8:43 AM |
| Intra-Cellular Therapies (ITCI) Upgraded at ValuEngine
www.americanbankingnews.com - March 11 at 2:23 PM |
| Intra-Cellular Therapies Inc Forecasted to Earn FY2018 Earnings of ($3.95) Per Share (ITCI)
www.americanbankingnews.com - March 7 at 11:51 AM |
| Intra-Cellular Therapies' (ITCI) "Outperform" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - March 7 at 10:59 AM |
| Intra-Cellular Therapies Inc (ITCI) Expected to Earn Q1 2018 Earnings of ($0.62) Per Share
www.americanbankingnews.com - March 7 at 7:55 AM |
| Equities Analysts Set Expectations for Intra-Cellular Therapies Inc's FY2019 Earnings (ITCI)
www.americanbankingnews.com - March 6 at 2:25 PM |
| SunTrust Banks Weighs in on Intra-Cellular Therapies Inc's FY2022 Earnings (ITCI)
www.americanbankingnews.com - March 5 at 9:50 AM |
| Intra-Cellular Therapies Inc to Post Q1 2018 Earnings of ($0.62) Per Share, Leerink Swann Forecasts (ITCI)
www.americanbankingnews.com - March 5 at 2:08 AM |
| Intra-Cellular Therapies (ITCI) Given Buy Rating at Cowen
www.americanbankingnews.com - March 3 at 8:22 PM |
| Intra-Cellular Therapies (ITCI) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - March 2 at 4:22 PM |
Intra-Cellular Therapies (NASDAQ:ITCI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Intra-Cellular Therapies (NASDAQ:ITCI) Income Statement, Balance Sheet and Cash Flow Statement
Intra-Cellular Therapies (NASDAQ ITCI) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
